Stock Markets June 3, 2026 01:08 PM

Lila Sciences Seeks Roughly $2 Billion in Series B at About $8.5 Billion Pre-Money

AI-driven startup negotiating major financing with public pension and Nvidia unit as backers amid rapid valuation growth

By Caleb Monroe NVDA

Lila Sciences is negotiating a roughly $2 billion Series B that would value the artificial intelligence research company at about $8.5 billion before the new capital, people familiar with the discussions said. The round is reported to be anchored by the California Public Employees’ Retirement System and Nvidia's NVentures. Lila has expanded quickly after a seed round and a $350 million Series A, positioning a general AI platform for autonomous scientific discovery that is trained on academic literature across materials, chemistry and life sciences.

Lila Sciences Seeks Roughly $2 Billion in Series B at About $8.5 Billion Pre-Money
NVDA

Key Points

  • Lila Sciences is negotiating a Series B of about $2 billion at an estimated $8.5 billion pre-money valuation; talks are described by people familiar with the matter.
  • The round is reported to be anchored by the California Public Employees’ Retirement System and NVentures, Nvidia’s investment vehicle.
  • Lila’s technology is a general AI platform trained on academic literature across materials, chemistry and life sciences, and the company has been creating labs to test these models.

Lila Sciences is in advanced discussions to raise approximately $2 billion in a Series B financing that would peg the company's pre-money valuation at about $8.5 billion, according to people familiar with the matter.

Those people said the planned round is expected to be anchored by the California Public Employees’ Retirement System and NVentures, the investment arm of Nvidia Corp. The potential financing would represent a significant step up from the private-market valuations Lila has held so far.

Over the past year the company's market value has surged on the basis of a central claim: that AI-driven tools can accelerate the pace of scientific discovery. Investors appear to be pricing that promise into Lila’s current fundraising discussions.

Prior to these talks, Lila disclosed a $350 million Series A that closed in October, which the company said lifted its valuation to above $1.3 billion. The business first emerged from stealth following a $200 million seed round.

The company has developed artificial intelligence trained on academic literature spanning materials science, chemistry and the life sciences, and has been building laboratories to test and validate those models. Rather than constructing narrow, domain-specific applications, Lila has built a general platform designed to enable autonomous scientific discovery across multiple technical domains.

At present the financing remains under negotiation; the discussions described by those familiar with the matter have not been confirmed as finalized. The outcome of the talks and any formal closing of the round could affect both Lila’s capitalization and its operational runway.

For investors and markets watching the intersection of AI and scientific research, Lila’s fundraising trajectory is an indicator of investor appetite for platform approaches that aim to combine machine learning with laboratory testing. The company’s prior funding milestones - the $200 million seed round and the $350 million Series A - mark a rapid fundraising cadence, and the new discussions, if completed, would substantially increase available capital to scale both model development and lab infrastructure.

Risks

  • The financing is still in negotiations - there is no guarantee the $2 billion Series B will close as discussed, creating uncertainty for stakeholders (impacts venture markets and corporate financing).
  • Lila’s heightened valuation is tied to the expectation that its AI tools will speed scientific discovery; if that promise is not realized, valuation and investor returns could be affected (impacts biotech, life sciences and AI-focused investing).
  • Translating AI models trained on literature into validated laboratory results presents execution risk, which could influence the company’s ability to scale its platform and realize projected benefits (impacts research labs, materials science and life-sciences sectors).

More from Stock Markets

Asian markets slip as tech and chip stocks weigh; Nikkei and KOSPI lead declines Jun 4, 2026 ASIC opens formal probe into three KPMG Australia partners amid whistleblower claims Jun 4, 2026 South Korea Labour Chief Urges Tech Giants to Share AI Windfall with Suppliers and Workers Jun 4, 2026 Markets Retreat as AI Momentum Pauses and U.S.-Iran Talks Stall Jun 4, 2026 U.S. Officials Held Early Talks on Taking Equity Stakes in AI Firms, NOTUS Says Jun 4, 2026